Houston Methodist opened a new tech hub in the Ion this week. Photo by Shannon O’Hara/Ion

Photos: Houston hospital opens tech hub in the Ion

innovation outpost

A Houston hospital has opened an innovation outpost in the Ion this week in order to showcase health tech innovation and connect with Houston innovators.

The Houston Methodist Tech Hub at Ion hub has officially opened. The 1,200-square-foot space was created in addition to the Center for Innovation Technology Hub that's in Houston Methodist’s flagship location in the Texas Medical Center, which opened in February 2020.

The new space, located on the lower level of the Ion, exists to serve as a common ground for innovators across industries to promote collisions and innovation, as well as interaction with Houston Methodist team members

“Our new Tech Hub at Ion supports not only our commitment to the Houston innovation community but also to the rapidly shifting healthcare industry,” Michelle Stansbury, vice president of innovation and IT applications at Houston Methodist, says in a statement. “We know we can’t solve the healthcare challenges of the future if we confine ourselves within our hospital walls or even within our own industry.

"We look forward to the collaborative space our new Tech Hub will provide and the future programming opportunities we can create together to inspire, challenge, and foster a spirit of innovation in our city.”

The new hub, according to the news release, also will host educational events, reverse pitch sessions, and more. Visitors can schedule a time to view the space or connect with the Houston Methodist innovation team by filling out a form online.

The hub, which was originally announced last year, is the latest partner to open within the Ion's space. Earlier this year, the organization announced other new tenants.

“Houston Methodist’s space at the Ion opens up even more opportunities for our start-up and entrepreneur community to embed and gain exposure to the latest innovations in health care, health technology, and digital health,” Jan E. Odegard, executive director of Ion, says. “This partnership and opportunity provided by Houston Methodist, a leading healthcare organization in the country, is a testament to the ecosystem we’re building and the talent within our building. Furthermore, Houston Methodist’s approach and appetite for cross-industry innovation and collaboration meshes seamlessly with the Ion’s ongoing plans to support Houston’s growing innovation community in industries and fields that will change the world.”

Both of Houston Methodist's tech hubs will showcase its latest technologies its implementing in its hospital system, including the "hospital of the future" it's building out in Cypress.

Collaborative effort

Photo by Shannon O’Hara/Ion

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”